Glipizide ER
GLUCOTROL XL
Pronunciation: GLIP-i-zide
What it isSulfonylurea that closes beta-cell KATP channels to release insulin; type 2 diabetes.
Why this oneIts shorter hypoglycemic tail than glyburide makes it a preferred sulfonylurea when kidney function is reduced.
What limits itMissed meals can provoke hypoglycemia; weight gain and progressive beta-cell failure limit durability.
Glipizide ER prescription history
Animated chart of estimated U.S. prescriptions per year, Diabetes meds (1923–2026). Glipizide ER enters in 1984 (estimated).
NO BOXED WARNINGS
Principal riskHypoglycemia
Sulfonamide
Sulfonamide-derived drug — label silent
A sulfonamide by structure, without the N4 aromatic amine or N1 heterocycle; the label carries no sulfonamide warning, and Khan lists it among drugs with no or weak evidence of cross-reactivity. Glimepiride, same bridge, is label-contraindicated.
Open the sulfonamide hypersensitivity presentation → · sources [n] are on its References slide.
Classes and tags
Clinical profile
Legacy pregnancy categoryMultiple / indication-, trimester- or formulation-dependent
Defining liabilitySevere hypoglycemia can occur, especially with excess dosing, poor intake or interacting drugs.
Open Glipizide ER in the interactive console ↗
Self-check
- What meal pattern can provoke glipizide ER hypoglycemia?
Missed meals. - What progressive cellular change limits glipizide ER durability?
Beta-cell failure.